Literature DB >> 15504709

Using the biologic license application or new drug application as a basis for the common technical document.

MaryAnn Foote1.   

Abstract

With the introduction of the common technical document (CTD), many writers in the biotech and pharmaceutical industries are now required to submit dossiers in this format. The format of the CTD is not extremely difficult from the familiar documents of the Biologic License Application (BLA) or New Drug Application (NDA). The CTD can be mapped to existing areas of the BLA or NDA. The components of the CTD are discussed and references to the current guidance worldwide are provided to assist the writer.

Mesh:

Year:  2004        PMID: 15504709     DOI: 10.1016/S1387-2656(04)10009-4

Source DB:  PubMed          Journal:  Biotechnol Annu Rev        ISSN: 1387-2656


  1 in total

1.  Regulatory Pathway for Licensing Biotherapeutics in Mexico.

Authors:  Carlos A López-Morales; Alejandra Tenorio-Calvo; Rodolfo Cruz-Rodríguez; Julio Sánchez Y Tepoz; Lahouari Belgharbi; Sonia Mayra Pérez-Tapia; Emilio Medina-Rivero
Journal:  Front Med (Lausanne)       Date:  2018-09-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.